Substance / Medication

Ramucirumab

Overview

Active Ingredient
ramucirumab
RxNorm CUI
1535922
Labeler: Eli Lilly and CompanyUpdated: 2025-12-18T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
3
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis.
Wu Rui, Yuan Sijia, Wang Yuxuan et al. · Clin Res Hepatol Gastroenterol · 2024
PMID: 39299442Meta-Analysis
Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.
Ren Ruiqi, Zhang Zhewei, Zhai Shaokun et al. · Eur J Clin Pharmacol · 2024
PMID: 39102039Meta-Analysis
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Galle Peter R, Kudo Masatoshi, Llovet Josep M et al. · Liver Int · 2021
PMID: 34173317Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ramucirumab (substance)
SNOMED CT
704259004
UMLS CUI
C2742502
RxNorm CUI
1535922
Labeler
Eli Lilly and Company

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.